JP2017532364A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532364A5
JP2017532364A5 JP2017523340A JP2017523340A JP2017532364A5 JP 2017532364 A5 JP2017532364 A5 JP 2017532364A5 JP 2017523340 A JP2017523340 A JP 2017523340A JP 2017523340 A JP2017523340 A JP 2017523340A JP 2017532364 A5 JP2017532364 A5 JP 2017532364A5
Authority
JP
Japan
Prior art keywords
methyl
phenyl
azaspiro
sulfanyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017523340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532364A (ja
Filing date
Publication date
Priority claimed from GBGB1419433.6A external-priority patent/GB201419433D0/en
Priority claimed from GBGB1419430.2A external-priority patent/GB201419430D0/en
Application filed filed Critical
Priority claimed from PCT/GB2015/053272 external-priority patent/WO2016067043A1/en
Publication of JP2017532364A publication Critical patent/JP2017532364A/ja
Publication of JP2017532364A5 publication Critical patent/JP2017532364A5/ja
Pending legal-status Critical Current

Links

JP2017523340A 2014-10-31 2015-10-30 ドーパミンd3レセプターのアンタゴニスト化合物 Pending JP2017532364A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1419430.2 2014-10-31
GB1419433.6 2014-10-31
GBGB1419433.6A GB201419433D0 (en) 2014-10-31 2014-10-31 Dopamine D3 receptor antagonist compounds
GBGB1419430.2A GB201419430D0 (en) 2014-10-31 2014-10-31 Dopamine D3 receptor antagonist compounds
PCT/GB2015/053272 WO2016067043A1 (en) 2014-10-31 2015-10-30 Dopamine d3 receptor antagonists compounds

Publications (2)

Publication Number Publication Date
JP2017532364A JP2017532364A (ja) 2017-11-02
JP2017532364A5 true JP2017532364A5 (enExample) 2018-11-29

Family

ID=54427799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523340A Pending JP2017532364A (ja) 2014-10-31 2015-10-30 ドーパミンd3レセプターのアンタゴニスト化合物

Country Status (17)

Country Link
US (3) US10000477B2 (enExample)
EP (1) EP3212637B1 (enExample)
JP (1) JP2017532364A (enExample)
KR (1) KR20170090422A (enExample)
CN (1) CN107108597B (enExample)
AU (1) AU2015340308B2 (enExample)
CA (1) CA2964103C (enExample)
DK (1) DK3212637T3 (enExample)
ES (1) ES2883831T3 (enExample)
IL (2) IL251725B (enExample)
MA (1) MA40858A (enExample)
MX (1) MX2017005484A (enExample)
NZ (1) NZ731118A (enExample)
RU (1) RU2017118562A (enExample)
SG (1) SG11201702982UA (enExample)
WO (1) WO2016067043A1 (enExample)
ZA (1) ZA201702765B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170090422A (ko) * 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
CN106883192B (zh) * 2017-03-30 2019-05-14 苏州汉德创宏生化科技有限公司 含氮类杂环抗肿瘤药物活性物恶唑基修饰的苯甲酸类化合物的合成方法
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
AU2020347274A1 (en) * 2019-09-13 2022-03-31 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
PE20221453A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AU2020364186B2 (en) 2019-10-09 2023-11-30 Novartis Ag 5-oxa-2-azaspiro(3.4)octane derivatives as M4 agonists
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
TW202136253A (zh) * 2019-12-19 2021-10-01 美商卡司馬療法公司 Trpml調節劑
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN116082192B (zh) * 2021-06-11 2024-09-13 重庆医药高等专科学校 一种反式4-(叔丁氧羰氨基)环己烷羧酸的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654305A (en) * 1970-01-26 1972-04-04 Robins Co Inc A H 5-azaspiro(2.4)heptanes
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
JP2003516967A (ja) 1999-12-16 2003-05-20 バイオストリーム セラピューティクス 1,3,4−置換ピペリジン類似体および嗜癖の治療におけるそれらの使用
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
MXPA04010552A (es) * 2002-04-26 2005-01-25 Schering Corp Antagonistas muscarinicos.
CN101044134A (zh) 2004-09-20 2007-09-26 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
US7977346B2 (en) 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
MX2008011016A (es) 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.
TW200813051A (en) * 2006-05-08 2008-03-16 Neurogen Corp Substituted azaspiro derivatives
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
GB0700786D0 (en) 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US8809552B2 (en) 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
ITMI20112329A1 (it) * 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
KR20170090422A (ko) * 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물

Similar Documents

Publication Publication Date Title
JP2017532364A5 (enExample)
RU2017118562A (ru) Соединения-антагонисты дофаминового d3-рецептора
RU2457207C2 (ru) Активаторы глюкокиназы
HRP20230789T1 (hr) Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6
RU2014152625A (ru) Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов
JP5015172B2 (ja) アリール−イソオキサゾロ−4−イル−オキサジアゾール誘導体
JP2018535999A5 (enExample)
JP2015517580A5 (enExample)
HRP20201068T1 (hr) Piridini supstituirani heteroarilom i postupci njihove upotrebe
JP2015533157A5 (enExample)
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
HRP20191327T1 (hr) 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
JP2010515734A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2014525444A5 (enExample)
RU2010137300A (ru) Модуляторы бета-амилоида
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2009121564A (ru) Азаадамантановые производные и способы применения
JP2007523208A5 (enExample)
JP2018507235A5 (enExample)
BR112019017171A2 (pt) compostos 1h-pirazolo[4,3-b]piridinas inibidores de pde1, composição farmacêutica e uso dos mesmos
RU2013139662A (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
JP2019529445A5 (enExample)